5e5 of anti-Her2 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human Her2, His Tag (Cat. No. HE2-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Biotinylated Human Her2, His,Avitag (Cat. No. HE2-H82E2) immobilized on SA Chip can bind Herceptin® with an affinity constant of 17 pM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Trastuzumab/Hyaluronidase | Approved | Genentech Inc | Herceptin Hylecta | United States | Breast Neoplasms | Genentech Inc | 2019-02-28 | Breast Neoplasms | Details | |
| Trastuzumab biosimilar (Allergan/Amgen) | ABP-980 | Approved | Synthon | Kanjinti | United States | Breast Neoplasms; Stomach Neoplasms | Amgen Inc | 2018-05-16 | Stomach Neoplasms; Breast Neoplasms | Details |
| Trastuzumab biosimilar (Biocon/Mylan) | Bmab-200; Myl-1401O; HerMyl-1401O | Approved | Biocon, Mylan Nv | CANMAb, Ogivri, Zedora, Hertraz | EU | Breast Neoplasms; Stomach Neoplasms | Mylan Sas | 2013-01-01 | Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms | Details |
| Trastuzumab/Pertuzumab | RO-7198574; RG-6264 | Approved | F. Hoffmann-La Roche Ltd | Phesgo | EU | Breast Neoplasms | Roche Registration Gmbh | 2020-06-29 | Breast Neoplasms | Details |
| Trastuzumab biosimilar (Biocad) | BCD-022 | Approved | Biocad | HERtiCAD | Russian Federation | Breast Neoplasms | Biocad | 2016-01-01 | Breast Neoplasms | Details |
| Trastuzumab biosimilar (Intas Pharmaceuticals) | Approved | Intas Biopharmaceuticals | Breast Neoplasms | Details | ||||||
| Trastuzumab biosimilar (Reliance Life Sciences) | R-TPR-016 | Approved | Reliance Life Sciences | TrastuRel | India | Breast Neoplasms | Reliance Life Sciences | 2015-01-01 | Breast Neoplasms | Details |
| Trastuzumab biosimilar (Pfizer) | PF-5280014; PF-05280014 | Approved | Pfizer Inc | Trazimera | Japan | Breast Neoplasms; Stomach Neoplasms | Pfizer Inc | 2018-07-26 | Stomach Neoplasms; Breast Neoplasms | Details |
| Trastuzumab biosimilar (Shanghai Henlius Biotech) | HLX-02 | Approved | Shanghai Henlius Biotech Co Ltd | Zercepac, 汉曲优 | Mainland China | Breast Neoplasms; Stomach Neoplasms | Shanghai Henlius Biopharmaceuticals Co Ltd | 2020-07-27 | Stomach Neoplasms; Breast Neoplasms | Details |
| Trastuzumab biosimilar (Dr. Reddy's Laboratories) | Approved | Dr. Reddy’S Laboratories Ltd | Hervycta | India | Breast Neoplasms | Dr. Reddy’S Laboratories Ltd | 2018-07-26 | Breast Neoplasms | Details | |
| Trastuzumab biosimilar (Zydus) | Approved | Zydus Cadila | Vivitra | India | Breast Neoplasms | Zydus Cadila | 2016-01-01 | Breast Neoplasms | Details | |
| Trastuzumab biosimilar (Samsung Bioepis) | SB-3; AMT-901 | Approved | Samsung Bioepis | Samfenet, Ontruzant | United States | Breast Neoplasms; Stomach Neoplasms | Samsung Bioepis Co Ltd | 2017-11-15 | Stomach Neoplasms; Breast Neoplasms | Details |
| Trastuzumab biosimilar (AXXO) | Approved | Axxo | Breast Neoplasms | Details | ||||||
| Pyrotinib Maleate | HTI-1001; SHR-1258; BLTN | Approved | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma of Lung; Breast Neoplasms; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Trastuzumab biosimilar (AryoGen Pharmed) | Approved | Aryogen Biopharma | AryoTrust | Stomach Neoplasms; Breast Neoplasms | Details | |||||
| Trastuzumab | R-597; RG-597; MKC-454; RO45-2317; huMAb4D5-8; Anti-HER2/neu-MAb | Approved | Genentech Inc | 赫赛汀, Herceptin | Mainland China | Stomach Neoplasms | Roche Pharma (Schweiz) Ag | 1998-09-25 | Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Urologic Neoplasms; Adenocarcinoma | Details |
| Dacomitinib | PF-299; PF-804; PF-299804; PF-00299804; PF-00299804-3; PF-00299804-03 | Approved | Pfizer Inc | Vizimpro | Mainland China | Carcinoma, Non-Small-Cell Lung | Pfizer Europe Ma Eeig | 2018-09-27 | Solid tumours; Head and Neck Neoplasms; Neoplasms; Liver Diseases; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Disitamab Vedotin | RC-48-ADC; RC48-ADC; RC-48 | Approved | RemeGen Co Ltd | 爱地希 | Mainland China | Carcinoma, Transitional Cell | RemeGen Co Ltd | 2021-06-08 | Solid tumours; Biliary Tract Neoplasms; Genital Diseases, Female; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Genital Neoplasms, Female; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Lapatinib Ditosylate Hydrate | GW-2016; GW-572016; GW-572016F | Approved | Novartis Pharma Ag, Glaxosmithkline Plc | Tykerb/Tyverb, 泰立沙, Tykerb, Tyverb | Mainland China | Breast Neoplasms | Glaxosmithkline Ag | 2007-03-13 | Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms | Details |
| Pertuzumab | R-1273; RG-1273; RO-4368451; rhuMab-2C4; RO-4368451-F01 | Approved | Genentech Inc | Perjeta, Omnitarg | Mainland China | Breast Neoplasms | Roche Pharma (Schweiz) Ag | 2012-06-08 | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Neoplasms, Unknown Primary; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Inetetamab | CMAB-302 | Approved | Shanghai Cp Guojian Pharmaceutical Co Ltd | Cipterbin, 赛普汀 | Mainland China | Breast Neoplasms | Shanghai Cp Guojian Pharmaceutical Co Ltd | 2020-06-17 | Breast Neoplasms | Details |
| Margetuximab | MGAH-22 | Approved | Macrogenics | Margenza | United States | Breast Neoplasms | Macrogenics Inc | 2020-12-16 | Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Afatinib Dimaleate | BIBW-2992; BIBW-2992-MA2 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | 吉泰瑞, Tovok, Giotrif, Gilotrif, Tomtovok | Mainland China | Carcinoma, Non-Small-Cell Lung | Boehringer Ingelheim International Gmbh | 2013-07-12 | Head and Neck Neoplasms; Rhabdomyosarcoma; Squamous Cell Carcinoma of Head and Neck; Renal Insufficiency; Neoplasms; Neuroectodermal Tumors; Liver Diseases; Endometriosis; Breast Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma | Details |
| Neratinib Maleate | CAN-030; HKI-272; PF-0528767; WAY-179272; PB-272 | Approved | Pfizer Pharmaceuticals Ltd (China) | Nerlynx, 贺俪安 | Mainland China | Breast Neoplasms | Excella Gmbh & Co Kg | 2017-07-17 | Solid tumours; Glioblastoma; Breast Neoplasms; Hepatic Insufficiency; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Ado-trastuzumab emtansine | RG-3502; R-3502; T-DM1; PRO-132365; RO-5304020 | Approved | Genentech Inc | Kadcyla, 赫赛莱 | Mainland China | Breast Neoplasms | Roche Pharma (Schweiz) Ag | 2013-02-22 | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Trastuzumab emtansine (Zydus Cadila) | ZRC-3256 | Approved | Zydus Cadila | Ujvira | India | Breast Neoplasms | Zydus Cadila | 2021-05-24 | Breast Neoplasms | Details |
| Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Pharmaceutical Co Ltd | 泰瑞沙, Tagrisso | Mainland China | Carcinoma, Non-Small-Cell Lung | Astrazeneca Ab | 2015-11-13 | Solid tumours; Carcinoma, Bronchogenic; Carcinoma; Thoracic Neoplasms; Bronchial Neoplasms; Lung Diseases; Respiratory Tract Neoplasms; Neoplasms, Nerve Tissue; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
| Fam-trastuzumab deruxtecan | DS-8201a; DS-8201 | Approved | Daiichi Sankyo Co Ltd | Enhertu | EU | Breast Neoplasms | Daiichi Sankyo Europe Gmbh | 2019-12-20 | Solid tumours; Ovarian Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms, Glandular and Epithelial; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Endometrioid | Details |
| Tucatinib | ARRY-380; ONT-380; MK-7119 | Approved | Array Biopharma | Tukysa | EU | Breast Neoplasms | Seagen Netherlands Bv | 2020-04-17 | Solid tumours; Stomach Neoplasms; Breast Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| Trastuzumab biosimilar (Celltrion) | CT-P6; CT-P06 | Approved | Celltrion | Herzuma | United States | Breast Neoplasms | Celltrion Inc | 2014-01-01 | Stomach Neoplasms; Breast Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical) | HS-022 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Trastuzumab biosimilar (BioIntegrator) | BI-Mab-03 | Phase 1 Clinical | Biointegrator | Breast Neoplasms | Details |
| Lapuleucel-T | BA-7072; DN-2402; APC-8024 | Phase 2 Clinical | Dendreon Uk Ltd | Carcinoma, Transitional Cell; Urogenital Neoplasms | Details |
| DZD-1516 | DZD-1516 | Phase 1 Clinical | Dizal (Jiangsu) Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| AU-101 | AU-101 | Phase 2 Clinical | Aurora Biopharma | Glioblastoma; Osteosarcoma; Breast Neoplasms | Details |
| Zenocutuzumab | MCLA-128 | Phase 2 Clinical | Merus | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| CIDeCAR | Phase 1 Clinical | Bellicum Pharmaceuticals, National Cancer Institute | Osteosarcoma | Details | |
| Puvitinib | Phase 1 Clinical | Suzhou Teligene Ltd | Solid tumours | Details | |
| Anti-HER2 CAR T-cell therapy (Baylor College of Medicine/The Hospital for Sick Children/Texas Children's Hospital/The Methodist Hospital System ) | Phase 1 Clinical | Baylor College Of Medicine, The Hospital For Sick Children, Texas Children'S Hospital, The Methodist Hosp Research Institute | Sarcoma | Details | |
| 68Ga-anti-HER2 nanobodies (Universite Libre de Bruxelles) | Phase 1 Clinical | Universite Libre De Bruxelles | Breast Neoplasms | Details | |
| BAT-8001 | BAT-8001 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Breast Neoplasms | Details |
| NeuCeptin | NeuCeptin | Phase 1 Clinical | Neuclone, Serum Institute Of India | Stomach Neoplasms; Breast Neoplasms | Details |
| HLX-22 | AC-101; HLX-22 | Phase 2 Clinical | Shanghai Henlius Biotech Co Ltd | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
| MT-5111 | MT-5111 | Phase 1 Clinical | Molecular Templates | Solid tumours; Neoplasms | Details |
| HER.CAR-CMV-specific-CTLs | HER.CAR-CMV-specific-CTLs | Phase 1 Clinical | Baylor College Of Medicine | Glioblastoma | Details |
| AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase 1 Clinical | Anrun Medicine Technology (Suzhou) Co Ltd | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms | Details |
| Varlitinib Ditosylate | QBT-01; ARRY-543; SPS-4370; ASLAN-001; ARRY-334543 | Phase 3 Clinical | Array Biopharma | Biliary Tract Neoplasms; Neoplasms; Pancreatic Neoplasms; Bile Duct Neoplasms | Details |
| Autologous-HER2-specific-T-cells | Autologous-HER2-specific-T-cells | Phase 1 Clinical | Baylor College Of Medicine | Sarcoma | Details |
| MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | Details |
| Iodine-131-SGMIB anti-HER2 monoclonal antibody | 131I-SGMIB-anti-HER2-VHH1; Iodine-131-SGMIB-anti-HER2-VHH1; CAM-H2; [131I]-SGMIB Anti-HER2-VHH1 | Phase 2 Clinical | Camel-Ids | Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms | Details |
| KSP-910638-G | KSP-910638G; KSP-910638-G | Phase 1 Clinical | University Of Michigan | Gastrointestinal Neoplasms | Details |
| TAC01-HER2 | TAC01-HER2 | Phase 2 Clinical | Triumvira Immunologics | Solid tumours | Details |
| AIP-303 | AIP-303 | Phase 2 Clinical | Advanced Imaging Projects | Breast Neoplasms | Details |
| GB-235 | GB-235 | Phase 1 Clinical | Genor Biopharma Co Ltd | Breast Neoplasms | Details |
| SSGJ-612 | SSGJ-612 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours | Details |
| GQ-1001 | GQ-1001 | Phase 1 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
| trastuzumab biosimilar (Hetero) | Ado-Trastuzumab biosimilar (Hetero) | Phase 3 Clinical | Hetero Drugs | Neoplasms | Details |
| ADXS-31164 | ADXS-HER2; ADXS-31164; ADXS-cHER2; ADXS31-164 | Phase 2 Clinical | University Of Pennsylvania | Solid tumours; Osteosarcoma | Details |
| Recombinant anti-HER2 humanized monoclonal antibody complex | B-002 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms | Details |
| Pertuzumab biosimilar(SL Pharma/Combio) | Phase 1 Clinical | Beijing Sl Pharmaceutical Co Ltd, Beijing Kangming Bio New Drug Development Co Ltd | Inflammatory Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details | |
| [89Zr]-Df-Trastuzumab | Phase 1 Clinical | University Of Alabama At Birmingham | Breast Neoplasms | Details | |
| Trastuzumab conjugate (BioIntegrator) | BI-CON-02 | Phase 1 Clinical | Biointegrator | Breast Neoplasms | Details |
| IBPM002BZ (Inbiopro Solutions) | IBPM-002BZ | Clinical | Inbiopro Solutions | Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms | Details |
| TGFBeta-resistant-HER2-EBV-CTLs | TGFBeta-resistant-HER2-EBV-CTLs | Phase 1 Clinical | Baylor College Of Medicine | Neoplasms | Details |
| ETBX-021 | ETBX-021 | Phase 2 Clinical | Nantbioscience, Etubics Corporation | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Neoplasms | Details | |
| Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis | Details |
| Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Research Institute | Central Nervous System Neoplasms | Details | |
| Pertuzumab biosimilar (Beijing SL) | KM-118; KM118 | Phase 1 Clinical | Breast Neoplasms | Details | |
| SHR-A1811 | SHR-A1811 | Phase 2 Clinical | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Timigutuzumab | GT-Mab-7.3-GEX | Phase 1 Clinical | Glycotope | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
| Epertinib | S-222611 | Phase 2 Clinical | Shionogi & Co Ltd | Neoplasms | Details |
| HER2/neu peptide vaccine (Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium) | Phase 2 Clinical | Fred Hutchinson/University Of Washington Cancer Consortium | Breast Neoplasms | Details | |
| Pertuzumab biosimilar (CinnaGen) | Phase 3 Clinical | Breast Neoplasms | Details | ||
| BMS-986186 | FS-102; BMS-986186 | Phase 1 Clinical | F-Star | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
| HER2(EQ)BBzeta/CD19 T cells (City of Hope) | Phase 1 Clinical | Mustang Bio, City Of Hope National Medical Center | Glioma | Details | |
| Recombinant anti-HER2 antibody (Anke Biotech) | Phase 3 Clinical | Anhui Anke Biotechnology (Group) Co Ltd | Breast Neoplasms | Details | |
| Multiple 4SCAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Breast Neoplasms | Details | |
| KSP-QRH-E3-IRDye800 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details | |
| HER-2 Specific CAR T Cell | Phase 1 Clinical | Ependymoma | Details | ||
| 99m-Tc labeled anti-HER2 single domain antibody (NanoMab) | 99mTc-NM-02 | Phase 1 Clinical | Nanomab Technology Ltd | Breast Neoplasms | Details |
| BDC-1001 | BDC-1001 | Phase 2 Clinical | Bolt Biotherapeutics | Solid tumours | Details |
| Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details | |
| Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) | Phase 1 Clinical | Shenzhen Main Luck Pharmaceuticals Inc | Breast Neoplasms | Details | |
| IMM-2902 | IMM-2902 | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours | Details |
| anti-HER2 ADC (Pfizer) | PF-06804103 | Phase 1 Clinical | Pfizer Inc | Breast Neoplasms | Details |
| Trastuzumab biosimilar (BioXpress Therapeutics) | BX-2318 | Clinical | Bioxpress Therapeutics Sa | Breast Neoplasms | Details |
| Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
| [18F]GE-226 | ABY-002; ABY-025; ABY-0125; 68GaABY025; GE-226; [68Ga]-ABY-025; GE-226-[18F]; [111]In-ABY-025; ABY-025-[68Ga]; ABY-025-[111In]; Gallium-68-ABY-025; Indium-111-ABY-025; Fluorine-18-GE-226 | Phase 3 Clinical | Affibody | Breast Neoplasms | Details |
| Trastuzumab biosimilar (Dong-A ST/Meiji Seika Pharma) | DA-3111; DMB-3111 | Phase 1 Clinical | Meiji Seika Pharma, Dong-A Pharmaceutical Co Ltd | Stomach Neoplasms; Breast Neoplasms | Details |
| HER2 cancer vaccine (BioLife Science) | PEV-6; PEV-6A; IMU-131 | Phase 2 Clinical | Pevion Biotech | Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma | Details |
| TPIV-100 (TapImmune) | TPIV-100 | Phase 2 Clinical | Mayo Clinic | Breast Neoplasms | Details |
| Tesevatinib | KD-019; KD-020; XL-647; EXEL-7647 | Phase 3 Clinical | Exelixis Inc | Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Carcinoma, Non-Small-Cell Lung; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis | Details |
| Multi-epitope HER2 peptide vaccine (Mayo Clinic) | Phase 1 Clinical | Mayo Clinic | Breast Neoplasms | Details | |
| Selatinib Ditosilate | QLNC-120 | Phase 2 Clinical | Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd | Stomach Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| IBPM003TZ (Inbiopro Solutions) | IBPM-003TZ | Clinical | Inbiopro Solutions | Breast Neoplasms | Details |
| PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | Details |
| BCD-147 | BCD-147 | Phase 1 Clinical | Biocad | Details | |
| MB-103 | MB-103 | Phase 1 Clinical | Mustang Bio, City Of Hope National Medical Center | Glioblastoma; Brain metastases | Details |
| Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase 1 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Neoplasms | Details |
| JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | Details |
| 89Zr-ss-Pertuzumab | Phase 1 Clinical | Genentech Inc | Breast Neoplasms; Metastatic breast cancer | Details | |
| AU-105 | AU-105 | Phase 2 Clinical | Aurora Biopharma | Glioblastoma | Details |
| Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Pertuzumab biosimilar (Hengrui Pharma) | SHR-1309 | Phase 1 Clinical | Metastatic breast cancer | Details | |
| MX-402 | MX-402 | Phase 1 Clinical | Medvax Technologies | Stomach Neoplasms | Details |
| Trastuzumab biosimilar (Tanvex Biopharma) | TX-05 | Phase 3 Clinical | Tanvex Biopharma | Breast Neoplasms | Details |
| Trastuzumab biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Serum Institute Of India, Neuclone | Stomach Neoplasms; Breast Neoplasms | Details | |
| RG-6148 | RG-6148; DHES-0815A | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Breast Neoplasms | Details |
| CT-0508 | Phase 1 Clinical | Carisma Therapeutics Inc | Carcinoma, Ductal; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Digestive System Neoplasms; Ovarian Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Inflammatory Breast Neoplasms; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms; Head and Neck Neoplasms; Solid tumours | Details | |
| BAT1006 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details | |
| KY-1701 | KY-1701 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| Recombinant humanized anti-HER2 antibody (Hisun Pharma) | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Breast Neoplasms | Details | |
| Pertuzumab（Hisun Pharm） | HS-627; HS627 | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Breast Neoplasms | Details |
| Coprelotamab | GB-221 | Phase 3 Clinical | Genor Biopharma Co Ltd | Breast Neoplasms | Details |
| Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hankemab) | Phase 1 Clinical | Hefei Hankemab Biotechnology Co Ltd | Solid tumours | Details | |
| DP-303c | DP-303c; DP303c | Phase 2 Clinical | Cspc Pharmaceutical Technology (Shijiazhuang) Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms | Details |
| IAH-0968 | IAH-0968; IAH0968 | Phase 2 Clinical | Shenghe (China) Biopharmaceutical Co Ltd | Solid tumours | Details |
| Pertuzumab(Jushi Biopharmaceutical ) | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Breast Neoplasms; Metastatic breast cancer | Details | |
| FCN-411 | FCN-411 | Phase 1 Clinical | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| GB-251 | GB-251; NBT-828; GB221-NBT828 ADC-1 | Phase 1 Clinical | Genor Biopharma Co Ltd, Newbio Therapeutics Inc | Breast Neoplasms; Metastatic breast cancer | Details |
| Trastuzumab biosimilar (United BioPharma) | UB-921 | Phase 1 Clinical | United Biopharma Inc | Breast Neoplasms | Details |
| Trastuzumab biosimilar (Alteogen) | ALT-L2; ALT-02; QL-1701 | Phase 3 Clinical | Alteogen Inc | Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms | Details |
| Recombinant anti-HER2 subdomain II humanized monoclonal antibody(Livzon) | LZM-005 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Breast Neoplasms | Details |
| Pertuzumab biosimilar (CTTQ) | TQB-2440 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| BB-1701 | BB-1701 | Phase 1 Clinical | Baili Sikang Biomedicine (Hangzhou) Co Ltd | Solid tumours | Details |
| AE-37/GP-2 vaccine | AE-37 (Generex Biotechnology Corporation) | Phase 2 Clinical | Generex Biotechnology Corp | Triple Negative Breast Neoplasms; Breast Neoplasms | Details |
| HER2.taNK | NK-92/5.28.z | Phase 1 Clinical | Nantkwest Inc | Glioblastoma | Details |
| 99mTc-HE3-G3 | 99mTc-HE3-G3; 99-mTc-HE-3-G-3; 99m-Tc-HE-3-G-3; 99mTc-(HE)3-G3 | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Details | ||
| 99mTc-HPArk2 | 99mTc-HPArk2; 99-mTc-HPArk-2 | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms | Details |
| SSGJ-705 | SSGJ-705 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours | Details |
| EX-101 | EX-101; EX101 | Phase 1 Clinical | Guangzhou ASM Biomedical Technology Co Ltd | Solid tumours | Details |
| RG-6194 | RG-6194; BTRC-4017A | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
| Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) | Phase 2 Clinical | University Of Michigan, Huazhong University Of Science And Technology, University Of Virginia Cancer Center, Medimmune | Breast Neoplasms | Details | |
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Peritoneal Neoplasms | Details | |
| DB-1303 | DB-1303 | Phase 2 Clinical | Duality Biologics Co Ltd | Solid tumours | Details |
| Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) | SIBP-01 | Phase 3 Clinical | Shanghai Institute Of Biological Products Co Ltd | Stomach Neoplasms; Breast Neoplasms | Details |
| Pertuzumab biosimilar() | XZP-KM118 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Breast Neoplasms | Details |
| XZP-5209 | XZP-5209 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| SSGJ-706 | SSGJ-706 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours; Lymphoma | Details |
| HL-02 | HL-02 | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Breast Neoplasms | Details |
| Trastuzumab biosimilar (Hualan Biological Engineering) | Phase 1 Clinical | Hualan Genetic Engineering Co Ltd | Stomach Neoplasms; Breast Neoplasms | Details | |
| TAS-0728 | TPC-107; TAS-0728 | Details | |||
| BAY-2927088 | BAY-2927088; BAY2927088 | Phase 1 Clinical | Bayer Healthcare Company Ltd, Bayer Ag | Carcinoma, Non-Small-Cell Lung | Details |
| Anbenitamab | KN-026 | Phase 3 Clinical | Suzhou Alphamab Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms | Details |
| Cinrebafusp alfa | PRS-343 | Phase 2 Clinical | Pieris Pharmaceuticals | Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms | Details |
| Fidasimtamab | IBI-315 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
| 99mTc- ADAPT6 | 99mTc- ADAPT6; ADAPT6; SNA-018 | Phase 1 Clinical | Uppsala University, Kth Royal Institute Of Technology | Breast Neoplasms | Details |
| TAA-013 | TAA-013 | Phase 3 Clinical | Tot Biopharm Co Ltd | Breast Neoplasms | Details |
| Pertuzumab biosimilar (Shanghai Henlius Biotech) | HLX-11 | Phase 1 Clinical | Shanghai Henlius Biotech Co Ltd | Breast Neoplasms | Details |
| A-166 | A-166 | Phase 2 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Lung Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Urologic Neoplasms; Carcinoma, Mucoepidermoid; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Urinary Bladder Neoplasms; Mouth Neoplasms; Lip Neoplasms; Laryngeal Neoplasms; Tonsillar Neoplasms; Uterine Cervical Neoplasms; Tongue Neoplasms; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Skin Neoplasms; Salivary Gland Neoplasms; Pancreatic Neoplasms; Rare Diseases; Esophageal Neoplasms; Cystadenocarcinoma, Mucinous; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Solid tumours; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
| Hemay-022 | Hemay-022 | Phase 3 Clinical | Tianjin Hemay Pharmaceutical Co Ltd, Xiajiang Hemei Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| ARX-788 | ARX-788; NCB-001 | Phase 3 Clinical | Ambrx | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms | Details |
| ALT-P7 | HM2-MMAE; ALT-P7 | Phase 1 Clinical | Alteogen Inc | Stomach Neoplasms; Breast Neoplasms | Details |
| Recombinant Humanized Anti-Human Epidermal Growth Factor Receptor Monoclonal Antibody and the Dolastatins Derivative DUO5 Conjugated | ZV0203; ZV203 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Zhejiang Zova Biotherapeutics Inc, Concortis Biosystems Corp | Solid tumours | Details |
| NJH-395 | NJH-395 | Phase 1 Clinical | Novartis Pharma Ag | Neoplasms | Details |
| ACE-1702 | ACE-1702 | Phase 1 Clinical | Acepodia Taiwan Subsidiary | Solid tumours; Stomach Neoplasms; Metastatic breast cancer; Neoplasm Metastasis | Details |
| BAY-2701439 | BAY-2701439 | Phase 1 Clinical | Bayer Ag | Neoplasms | Details |
| Sunvozertinib | DZD-9008 | Phase 2 Clinical | Dizal (Jiangsu) Pharmaceutical Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung | Details |
| ZW-49 | ZW-49 | Phase 1 Clinical | Zymeworks Inc | Stomach Neoplasms; Neoplasms; Breast Neoplasms | Details |
| Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) | HS-630; HS630 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Breast Neoplasms | Details |
| Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Trastuzumab biosimilar(Aprogen/Nichi-Iko) | AP-06 | Phase 3 Clinical | Aprogen, Nichi-Iko Pharmaceutical Co Ltd | Breast Neoplasms | Details |
| SHR-A1201 | SHR-A1201 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Breast Neoplasms | Details |
| Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) | B-003 (Shanghai Pharma) | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms | Details |
| MBS-301 | MBS-301 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
| M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | M-802 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Breast Neoplasms | Details |
| Trastuzumab duocarmazine | SYD-985 | Phase 3 Clinical | Synthon | Solid tumours; Stomach Neoplasms; Breast Neoplasms; Endometrial Neoplasms | Details |
| Zanidatamab | ZW-25 | Phase 3 Clinical | Zymeworks Inc | Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Gastrointestinal Neoplasms | Details |
| LCB14-0110 | FS-1502; LCB14-0110 | Phase 2 Clinical | Legochembio | Solid tumours; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| SBT-6050 | SBT-6050; SBT6050 | Phase 2 Clinical | Silverback Therapeutics Inc | Solid tumours; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BDTX-189 | BDTX-189 | Phase 2 Clinical | Black Diamond Therapeutics | Solid tumours | Details |
| MRG-002 | MRG-002 | Phase 2 Clinical | Shanghai Miracogen Inc | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| ARV-471 | ARV-471 | Phase 2 Clinical | Arvinas Inc | Breast Neoplasms | Details |
| HER2/Neu GP2 vaccine(Greenwich LifeSciences Inc/NuGenerex Immuno Oncology) | GLSI-100 | Phase 3 Clinical | Antigen Express Inc, Norwell Inc | Breast Neoplasms | Details |
| Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
| Recombinant anti-HER2 antibody-Tub114 | DAC-001; DX126-262 | Phase 2 Clinical | Hangzhou Dac Biotech Company Ltd | Stomach Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details |
| ZN-A-1041 | ZN-A-1041 | Phase 1 Clinical | Suzhou Zanrong Pharmaceutical Technology Co Ltd | Solid tumours; Breast Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
